Since 5-fluorouracil (5’FU) and cisplatin have become a global standard regimen for first-line treatment of metastatic GC [28], we next examined whether IFITM3 contributes to chemoresistant property of GC cells attributed by treatments of 5’FU and cisplatin. This evidence concerns the gene IFITM3 and gastric cancer.